Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in adult chronic primary immune thrombocytopenia (ITP)
CTR20232074Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in chronic primary immune thrombocytopenia (ITP), sponsored by Innovent Biologics. Started Oct 2023; status: active.
02
Drugs
orelabrutinib
03
Conditions
chronic primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20232074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232074.